Advanced Solid Tumors With KRAS G12C Mutations

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Frontier Medicines
Frontier MedicinesCA - South SF
1 program
1
FMC-376Phase 1/21 trial
Active Trials
NCT06244771Recruiting403Est. Apr 2028

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
Frontier MedicinesFMC-376

Clinical Trials (1)

Total enrollment: 403 patients across 1 trials

NCT06244771Frontier MedicinesFMC-376

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Start: Feb 2024Est. completion: Apr 2028403 patients
Phase 1/2Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4h ago

Office Administrator

SystImmune
4h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
4h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
4h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
4h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 403 patients
1 companies competing in this space

Related Indications

Breast Cancer(577)Prostate Cancer(385)Non-small Cell Lung Cancer(378)Multiple Myeloma(359)Cancer(249)Advanced Solid Tumors(226)Acute Myeloid Leukemia(209)Neoplasms(199)Colorectal Cancer(171)Melanoma(170)